Patients receiving Ra-223 after the EMA restriction were at later stages of the disease compared with the pre-restriction cohort, as suggested by the higher frequency of lymphadenopathies, higher number of bone metastases, and previously administered chemotherapy, as well as by the higher PSA and lower haemoglobin levels (Table 1). This evidence concerns the gene KLK3 and Lymphadenopathy.